CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1195-1201

  Cameron, D A ^a   White, J M ^c   Proctor, S J ^b   Prescott, R J ^a   Leonard, R C F ^a   Angus, B ^c   Cook, M K ^c   Dawes, P J D K ^c   Dawson, A A ^c   Evans, R G B ^c   Galloway, M J ^c   Harris, A L ^c   Heppleston, A ^c   Home, C H W ^c   Krajewski, A S ^c   Lennard, A L ^c   Lessells, A M ^c   Lucraft, H H ^c   MacGillivray, J B ^c   Mackie, M J ^c   Parker, A C ^c   Roberts, J T ^c   Taylor, P R A ^c   Thompson, W D ^c   more..

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NONE

Author keywords

CHOP; non Hodgkin's lymphoma; Randomised trial; Survival

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXIN ANALYSIS; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, HIGH-GRADE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISOLONE; SURVIVAL RATE; VINCRISTINE; VINDESINE;

EID: 8544249834     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00051-8     Document Type: Article

References (22)

1. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975, 1, 248-250.
2. Schein PS, DeVita VT Jr, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisolone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976, 85, 417-422.
3. Fisher RI, DeVita VT Jr, Johnson BL, Simon R, Young RC. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 1977, 63, 177-182.
4. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986, 104, 757-765.
5. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985, 102, 596-602.
6. Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advance diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991, 9, 25-38.
7. Goldie JH, Goldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep (3) 1982, 66, 439-449.
8. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982, 60, 693-697.
9. Leonard RCF, Lucraft HH, Proctor SJ, et al. Methylprednisolone, etoposide, vindesine and chlorambucil (PEEC) alone or alternating with CHOP as initial or salvage therapy for non-Hodgkin's lymphoma. Scot Med J 1988, 33, 360-362.
10. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982, 49, 2112-2135.
11. Hayward RL, Leonard RCF, Prescott RJ. A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 1991, 63, 945-952.
12. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med (14) 1993, 329, 987-994.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
15. Leonard RCF, Prescott RJ, Mao J-H, White JM. Successful application of a previously derived prognostic index in the analysis of a randomised trial of 281 patients with high grade non-Hodgkin's Lymphoma (HIGNHL). Ann Oncol (10) 1993, 4, 853-856.
16. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328, 1002-1006.
17. Horning SJ, Chao NJ, Negrin RS, et al. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data. Ann Oncol (Supp 1) 1991, 2, 47-50.
18. Hainsworth JD. Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leukemia Lymphoma (Supp 1) 1993, 10, 65-72.
19. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L. Cardiotoxicity 4-20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
20. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ. Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 1989, 24, 243-245.
21. Fisher RI, DeVita VJ Jr, Hubbard SM, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequence of ProMACE and MOPP chemotherapy. Ann Intern Med 1983, 98, 304-309.
22. Goldie JH, Goldman AJ. A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 1979, 63, 1727-1733.